Brain, Vol. 125, No. 8, 1875-1886,
August 2002
© 2002 Guarantors of Brain
Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment
Departments of 1 Neurology and 2 Clinical Neurophysiology, Rudolf Magnus Institute for Neurosciences, University Medical Centre Utrecht, The Netherlands
Correspondence to: L. H. Van den Berg, MD, PhD, Department of Neurology, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands E-mail: l.h.vandenberg{at}neuro.azu.nl
We performed a long-term follow-up study of 11 patients with multifocal motor neuropathy (MMN) who received maintenance treatment with intravenous immunoglobulins (IVIg). Patients were treated initially with one full course of IVIg (0.4 g/kg for 5 days) followed by one IVIg infusion (0.4 g/kg) every week. During follow-up, the frequency and dosage of IVIg infusions were determined for each patient and ranged from one infusion every 1 to 7 weeks and an average dose of 7 to 48 g per week. During the 4- to 8-year follow-up period, muscle strength was assessed by measuring the MRC (Medical Research Council) sumscore of 20 muscle groups and by performing hand-held dynamometry on a selection of weak muscle groups. Systematic electrophysiological studies were performed before treatment and each year during IVIg maintenance treatment. Disability was assessed with the upper limb and lower limb subscales of the Guy’s Neurological Disability Scale before treatment, after the first full course of IVIg and at the last follow-up examination. Muscle strength improved significantly within 3 weeks of the start of IVIg treatment and was still significantly better at the last follow-up examination than before treatment, even though it decreased slightly and significantly during the follow-up period. Upper limb disability was significantly better after the first full course of IVIg than before treatment. Conduction block disappeared in six nerve segments but new conduction block appeared in eight nerve segments during the follow-up period. Changes consistent with improvement (remyelination or reinnervation) occurred in 13 nerves during follow-up and changes consistent with worsening (demyelination or axon loss) occurred in 14 nerves. Electrophysiological changes consistent with improvement were significantly associated with the presence of conduction block before IVIg treatment. In conclusion, IVIg maintenance treatment has a beneficial long-term effect on muscle strength and upper limb disability but may not prevent a slight decrease in muscle strength. The electrophysiological findings imply that IVIg treatment favourably influences the mechanisms of remyelination or reinnervation but that axon loss cannot be prevented.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y A Rajabally Multifocal motor neuropathy: review of a treatable immune mediated disorder Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-M Leger, K Viala, F Cancalon, T Maisonobe, B Gruwez, T Waegemans, and P Bouche Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 93 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Triggs and D. Cros Case 40-2007 -- A 38-Year-Old Man with Weakness in the Hands N. Engl. J. Med., December 27, 2007; 357(26): 2707 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Slee, A. Selvan, and M. Donaghy Multifocal motor neuropathy: The diagnostic spectrum and response to treatment Neurology, October 23, 2007; 69(17): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain, August 1, 2007; 130(8): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Lange, L. H. Weimer, W. Trojaborg, R. E. Lovelace, C. L. Gooch, and L. P. Rowland Multifocal Motor Neuropathy With Conduction Block: Slow But Not Benign Arch Neurol, December 1, 2006; 63(12): 1778 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. H. Van Asseldonk, L. H. Van den Berg, G. H. Wieneke, J. H. J. Wokke, and H. Franssen Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain, September 1, 2006; 129(Pt 9): 2447 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chaudhry and M. Swash Multifocal motor neuropathy: is conduction block essential? Neurology, August 22, 2006; 67(4): 558 - 559. [Full Text] [PDF]
|
|
|
|
|
|
J T H Van Asseldonk, L H Van den Berg, S Kalmijn, R M Van den Berg-Vos, C H Polman, J H J Wokke, and H Franssen Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Moroni, M. Bugiani, C. Ciano, R. Bono, and D. Pareyson Childhood-onset multifocal motor neuropathy with conduction blocks Neurology, March 28, 2006; 66(6): 922 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Ghosh, A Virgincar, R Kennett, M Busby, and M Donaghy The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1269 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Beekman, L. H. van den Berg, H. Franssen, L. H. Visser, J.T.H. van Asseldonk, and J. H.J. Wokke Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy Neurology, July 26, 2005; 65(2): 305 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vucic, K. R. Black, P. S. T. Chong, and D. Cros Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg Neurology, October 12, 2004; 63(7): 1264 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Terenghi, A. Cappellari, A. Bersano, M. Carpo, S. Barbieri, and E. Nobile-Orazio How long is IVIg effective in multifocal motor neuropathy? Neurology, February 24, 2004; 62(4): 666 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rojas-Garcia, E. Gallardo, I. de Andres, N. de Luna, C. Juarez, P. Sanchez, and I. Illa Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab Neurology, December 23, 2003; 61(12): 1814 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Pestronk, J Florence, T Miller, R Choksi, M T Al-Lozi, and T D Levine Treatment of IgM antibody associated polyneuropathies using rituximab J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 485 - 489. [Abstract] [Full Text] [PDF]
|
|